NOVEL ANTIBODIES AGAINST EPHA2 FOR RESEARCH, DIAGNOSIS, AND TREATMENT OF CANCER

Tech ID: 30477 / UC Case 2009-106-0

Invention Novelty

A novel monoclonal human antibody specific to the cell-surface exposed protein EphA2, which is over-expressed in many forms of cancer and is a validated therapeutic target.

Value Proposition

Many forms of cancer, most notably basal-like breast cancers, induce the over-expression of a cell-surface exposed protein EphA2, making it a potent biomarker for cancer diagnosis as well as a therapeutic target. Using a unique, high-throughput phage-display screening approach, UCSF researchers have successfully identified a novel human monoclonal antibody that recognizes a new epitope of EphA2, and upon recognizing EphA2 on the cell surface is able to be efficiently internalized. Internalizing antibodies are essential technologies for the targeted delivery of anti-cancer drugs.

This novel invention provides the following advantages:

  • A new tool with which to target EphA2: a validated therapeutic target for many forms of cancer, including basal-type breast cancers
  • Targeted delivery of anti-cancer drugs through the use of internalizing antibodies with cancer-specific epitopes

Technology Description

UCSF researchers have taken a high-throughput screening approach to identify novel human antibodies against cell-surface proteins commonly over-expressed in cancer cells. The approach involves rounds of selection of a human antibody phage-display library for internalization in a human breast cancer cell line, and further enrichment of antibodies that bind human proteins of interest by expressing them (in their surface-displayed form) in yeast. The result of this approach has produced a novel human antibody against the validated cancer target EphA2.

Application

  • Research tool
  • Diagnostic
  • Therapy for basal-like breast cancers or other forms of cancer

Looking for Partners

To develop and commercialize this novel antibody as a research tool for the study of, diagnosis of, or therapy for certain forms of cancer. 

Stage of Development

Preclinical

Related Materials

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 10,406,225 09/10/2019 2009-106
Mexico Issued Patent 349662 08/08/2017 2009-106
China Issued Patent 201180044968.9 09/28/2016 2009-106
United States Of America Issued Patent 9,446,125 09/20/2016 2009-106
Russian Federation Issued Patent 2598711 09/06/2016 2009-106
United States Of America Issued Patent 9,220,772 12/29/2015 2009-106
Australia Issued Patent 2011280893 03/19/2015 2009-106
South Africa Issued Patent 2013/00573 03/26/2014 2009-106
 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Keywords

Antibody, Cancer, Oncology, EphA2

Categorized As